This technology includes a series of small molecule TRHR agonists for the treatment of cancer-related fatigue. In particular, PTLS-04 and PTLS-11 have shown excellent TRHR agonist activities in mouse and human cells and have improved metabolic profile compared to TRI I and taltirelin. Additional work is being done to further optimize the series by designing and synthesizing additional compounds.